U.S. Minimally Invasive Surgical Instruments Market Summary

The U.S. minimally invasive surgical instruments market size was valued at USD 8.28 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 10.3% from 2024 to 2030. This strong growth is primarily driven by factors such as high purchasing power among patients, the increasing prevalence of chronic disorders including cardiac, orthopedic, and gastrointestinal conditions, and the availability of favorable reimbursement policies. Additionally, the presence of government initiatives supporting quality healthcare infrastructure further strengthens the market outlook by ensuring wider accessibility of advanced surgical techniques.

In 2023, the U.S. accounted for 26.18% of the global minimally invasive surgical instruments market, showcasing its significant role in driving worldwide demand. The increasing adoption of minimally invasive surgeries (MIS) across diverse specialties such as esthetics, dentistry, orthopedics, thoracic, cardiology, and gynecology is expected to fuel market expansion. Moreover, the growing geriatric population and the rising incidence of obesity are contributing to an increased risk of chronic illnesses, thereby further propelling the adoption of MIS procedures due to their reduced trauma, shorter recovery times, and improved patient outcomes.

Key Market Trends & Insights

• The handheld device segment dominated the market with a share of 22.1% in 2023. Handheld instruments play a critical role in MIS procedures as they simplify complex surgeries, reduce the extent of incisions, and minimize surgical complications. Their use has been associated with reduced postoperative pain, shorter hospital stays, and faster recovery, making them a preferred choice for surgeons and patients alike. With continuous technological advancements, handheld devices are expected to maintain a strong position within the overall market.
• The gynecological segment held the largest market share of 17.89% in 2023. Procedures in this segment typically involve specialized surgical tools and miniature scopes, which are inserted either through small incisions in the abdominal area or transvaginally. Increasing awareness among healthcare professionals about advanced surgical techniques, including laparoscopic and nerve-sparing electrosurgery for hysterectomies, has significantly enhanced procedural safety and outcomes. This growing shift toward advanced gynecological surgical practices is expected to drive steady growth in this segment over the forecast period.
• The hospital segment emerged as the leading end-use category with a share of 63.69% in 2023. Hospitals perform a higher volume of surgeries compared to other healthcare facilities, supported by the presence of skilled professionals, favorable reimbursement systems, and extensive access to advanced medical equipment. Investments in minimally invasive surgical instruments are gradually increasing across hospitals, reflecting their strategic role in improving patient care and procedural efficiency. The centralized infrastructure and focus on quality care delivery continue to strengthen the dominance of hospitals in this market.
• The ambulatory surgical centers (ASCs) segment is expected to witness the highest growth during the forecast period. Factors contributing to this growth include the increasing patient preference for same-day surgeries, significant cost savings compared to hospital-based care, shorter waiting times, and convenience of services. The growing number of patients requiring surgical interventions, coupled with advancements in MIS that make procedures safer and less invasive, are driving the rapid expansion of ASCs across the U.S.

Order a free sample PDF of the U.S. Minimally Invasive Surgical Instruments Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2023 Market Size: USD 8.28 billion
• 2030 Projected Market Size: USD 16.41 billion
• CAGR (2024 - 2030): 10.3%

Key Companies & Market Share Insights

Some prominent U.S. minimally invasive surgical instruments companies include Medtronic, Siemens Healthineers AG, Johnson & Johnson Services, GE Healthcare, Abbott, Intuitive Surgical, ArthroCare Corporation, NuVasive, and Zimmer Biomet. These companies have a strong presence in the market and offer a wide range of minimally invasive surgical instruments.

However, there is a constant increase in number of players operating in this industry. Companies have adopted various strategies such as product launches, mergers & acquisitions, and to gain a competitive advantage. In addition, companies are more focused on developing and receiving FDA clearance for technologically advanced minimally invasive surgical instruments with higher efficiency and accuracy. For instance, in December 2021, Intuitive Surgical, Inc. received FDA clearance for its 8 mm SureForm 30 Curved-Tip Stapler. 

Key Players

• Medtronic
• Siemens Healthineer AG
• Ethicon, Inc. (Johnson & Johnson)
• Depuy Synthes
• GE Healthcare
• Abbott Laboratories
• Intutive Surgical, Inc.
• Nuvasive, Inc.
• Zimmer Biomet

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The U.S. minimally invasive surgical instruments market is poised for significant growth, supported by rising healthcare investments, technological innovations, and the increasing adoption of MIS procedures across a wide range of medical fields. The dominance of handheld devices, hospitals, and gynecology-related surgeries highlights key areas of market strength, while the fast growth of ambulatory surgical centers reflects evolving patient preferences for cost-effective and efficient care. With the rising burden of chronic diseases and a growing elderly population, the demand for safer and quicker surgical interventions is set to accelerate, ensuring strong market expansion through 2030.